Hematology Deal Benchmarks
Leukemia, lymphoma, myeloma, sickle cell, and hemophilia deal benchmarks. Benchmarks derived from 46 verified transactions.
46
Total Deals
$611M
Avg Upfront
5
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
15
license
17
acquisition
11
collaboration
2
option
0
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Keros Therapeutics → Takeda anemia | license | $200M | $200M | Dec 2024 |
Curon Biopharmaceutical → Merck hematologic_malignancies | acquisition | $700M | $1.3B | Oct 2024 |
Disc Medicine → Novo Nordisk thalassemia | license | $100M | $1.2B | Sep 2024 |
MorphoSys → Novartis myelofibrosis | acquisition | $2.9B | $2.9B | Jan 2024 |
Prime Medicine → Bristol Myers Squibb Prime gene editing CAR-T | collaboration | $110M | $3.6B | Jan 2024 |
Arcellx → Kite (Gilead) CART-ddBCMA | collaboration | $85M | — | Nov 2023 |
Legend Biotech → Novartis LB2102 | license | $100M | $1.2B | Nov 2023 |
CTI BioPharma → Sobi myelofibrosis | acquisition | $1.7B | $1.7B | Jul 2023 |
Kartos Therapeutics → Roche myelofibrosis | license | $200M | $1.5B | Jul 2023 |
Rigel Pharmaceuticals → Kissei Pharmaceutical itp | license | $17M | $200M | Jul 2023 |
Benchmark Your Hematology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 46 verified hematology transactions.
Run Hematology Benchmark